Aclarion's Remarkable Progress in Scan Volume Growth
Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company specializing in augmented intelligence and biomarkers, has recently shared significant updates regarding its operational achievements. The Company's innovative solution, Nociscan, has garnered considerable attention as it has demonstrated an impressive year-over-year scan volume increase of 132% from mid-2024 to mid-2025. This growth is largely attributed to enhanced physician adoption and successful collaborations with insurance providers, particularly in the UK.
Consistent Scan Volume Growth and Future Expectations
For the first time, Aclarion achieved back-to-back quarters of scan volume growth, a milestone that indicates a positive trend for the Company’s prospects in the healthcare technology sector. The steady rise in scan volume is crucial for increasing revenue streams and securing favorable insurance reimbursements. The Company has activated multiple commercial sites in the U.S. and onboarded CLARITY study sites, with three out of the four major private insurance carriers in the UK now providing coverage for Nociscan. Aclarion believes this momentum will translate into ongoing growth through the remainder of the year and beyond.
Strategic Catalysts for Growth
Aclarion is focusing on two primary catalysts to enhance its value proposition. The first is expanding scan volume growth in the UK, where limitations on insurance approvals have been alleviated. Currently, over 5.2 million individuals in the UK can access Nociscan through their insurance plans. The Company intends to leverage partnerships, notably with The London Clinic, to bolster awareness and adoption of Nociscan, which has led to significant increases in scan volumes reported thus far. Management is optimistic about the continuing acceleration of this growth.
Insights from Aclarion's Leadership
“The first half of 2025 has been pivotal, marked by remarkable growth in scan volumes. Our ongoing commercial traction and the accumulating clinical and economic evidence, supported by both real-world studies and the CLARITY trial, bolster our confidence,” stated Brent Ness, CEO of Aclarion. “With the recent positive payer coverage experiences, we are optimistic that the payer community will continue to embrace Nociscan, promoting consistent revenue growth.”
Advancements in the CLARITY Trial
The second key growth driver is the ongoing CLARITY trial, which aims to establish a vital link between Nociscan’s AI-based algorithm and improved patient surgical outcomes. The trial is poised to be one of the first prospective randomized studies bridging non-invasive technology to enhance surgical practices for chronic low back pain patients. With financial commitments to clinical excellence, the Company anticipates significant results that could influence widespread insurance coverage in the U.S.
Significant Milestones and Future Directions
Aclarion has engaged with eight sites during the first phase of the study, with active participation from four fully onboarded locations, including the Texas Back Institute and the University of Miami Health. The initial patient for the CLARITY trial was enrolled recently, with projections to complete full enrollment of 300 patients by late 2026. An internal analysis on early clinical outcomes will provide insights into Nociscan's potential effectiveness in achieving better outcomes. This analysis is set to reveal preliminary findings by mid-2026.
Publication of Key Clinical Evidence
Establishing clinical evidence is vital for endorsing insurance coverage for Nociscan. Recently, the journal Clinicoeconomics and Outcomes Research published an independent cost-effectiveness analysis showing that Nociscan is not only more effective but also significantly less expensive compared to provocative discography. The study illustrated a savings of over $1,700 per patient while improving surgical outcomes, thereby strengthening the case for broad payer coverage.
Aclarion's Commitment to Innovation and Growth
The importance of continued innovation in the medical field cannot be overstated, especially concerning chronic low back pain—a condition impacting millions globally. Aclarion's dedication to leveraging advanced technology through Nociscan places them at the forefront of the healthcare technology realm. With ongoing trials and collaborations, Aclarion is effectively positioning itself for substantive growth in the forthcoming years, aiming to change the landscape of pain management.
Frequently Asked Questions
What recent achievements has Aclarion made?
Aclarion reported a 132% increase in scan volume year-over-year and has achieved two consecutive quarters of growth.
How does Nociscan benefit healthcare providers?
Nociscan provides objective measurements to help providers identify the source of chronic low back pain, aiding in better treatment planning.
What is the significance of the CLARITY trial?
The CLARITY trial is expected to validate the connection between AI technology and improved surgical outcomes for patients, influencing insurance coverage decisions.
What are the financial expectations for Aclarion?
The Company is projected to continue revenue growth, supported by clinical evidence and broader adoption of Nociscan in multiple markets.
How is Aclarion enhancing its market strategy?
Aclarion is strategizing intensively on physician education and expanding its presence in the UK to maximize scan volume growth.
